Correlation between APRI, FIB-4 and GPR Indices to Fibroscan and HBeAg Status in Patients with Chronic Hepatitis B
DOI:
https://doi.org/10.24293/ijcpml.v27i3.1718Keywords:
APRI, FIB 4, GPR, fibroscan, chronic hepatitis B, HBeAgAbstract
Liver fibrosis is a complication of chronic hepatitis B. Early detection of liver fibrosis is important for therapy. The aspartate aminotransferase index (AST)-to-platelet ratio index (APRI) and the fibrosis index based on 4 factors (FIB-4) in chronic hepatitis B have been widely studied despite the inconsistent results. Research on other serum markers is extensively carried out, including Gamma-Glutamyl Transpeptidase (GGT)-to-platelet ratio (GPR). Previous studies have shown that the GPR index was more accurate than APRI and FIB-4. HBeAg status is an indication for therapy. There have not been many studies on the correlation of serum markers with HBeAg status. This study aimed to determine the correlation of APRI, FIB-4, and GPR with Fibroscan and HBeAg status in chronic hepatitis B patients. A cross-sectional study was carried out from June to September 2020 and found 50 chronic hepatitis B patients. Platelet count was measured using a Sysmex XN-1000 hematology device; AST, alanine aminotransferase (ALT), and GGT levels were measured using the Dimension RXL clinical chemistry device; and the degree of fibrosis was determined using transient elastography (Fibroscan). Spearman correlation test was used in this study for the correlation analysis. The results showed a significant correlation between APRI, FIB-4 and GPR indices with Fibroscan (r=0.454, p 0.001; r=0.610, p < 0.001; r=0.540, p < 0.001, respectively). A significant correlation was found between APRI, FIB-4 and GPR indices with negative (-) HBeAg (r=0.486, p 0.004; r=0.648, p < 0.001; r=0.595, p < 0.001, respectively). In addition, a significant correlation was found between FIB-4 and positive (+) HBeAg (r=0.499, p 0.049), but no correlation was found between APRI and GPR with positive (+) HBeAg (r=0.295, p 0,267; r=0.386, p 0.140, respectively).Downloads
References
Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet, 2018; 392(10161):
-24.
Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection a review. JAMA-J Am Med Assoc, 2018; 319(17): 1802-13.
Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology-a clinical textbook. 9th Ed., Germany, Flying Publisher, 2018; 423.
Adrianti E, Kurniawan BL, A. Samad I. Comparisons of fibro Q index and FIB-4 in various stages of chronic B hepatitis. Indones J Clin Pathol Med Lab, 2018; 25(1): 68.
Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z, et al. Non-invasive
biomarkers in assessment of liver fibrosis in patients with HBeag negative chronic hepatitis B. Open Access Maced J Med Sci, 2018; 6(6): 1052-8.
Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of
significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT?2 ULN A retrospective cohort
study. Med (United States), 2017; 96(12): 1-7.
Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of hepatitis B and C Viruses infections:
Synergy of sex hormones and immune responses?. Front Immunol, 2018; 9: 1-7.
Wang RQ, Zhang QS, Zhao SX, Niu XM, Du JH, et al. Gamma-glutamyl transpeptidase to platelet ratio
index is a good non-invasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. J Int Med Res, 2016; 44(6): 1302-13.
De Lédinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices, 2010; 7(6): 811-23.
Li Q, Chen L, Zhou Y. Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels. Sci Rep [Internet]. 2018; 8(1): 1-7. Available from: http://dx.doi.org/10.1038/s41598-018-23646-2 (accessed at 5 June, 2020).
Liu D, Zhang Z, Wang Y, Ding R, Zhou X, et al. Comparative evaluation of GPR versus APRI and FIB-4
in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepatol, 2018; 25(5): 581-9.
Kim WR, Berg T, Asselah T, Flisiak R, Fung S, et al. Evaluation of APRI and FIB-4 scoring systems for
non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol [Internet]. 2015.
Available from: http://dx.doi.org/10.1016/j.jhep.2015.11.012 (accessed at 5 June, 2020).
Bishop ML, Fody EP, Schoeff LE. Clinical chemistry th -principles, techniques and correlations. 8 Ed.,
Philadelphia, Wolters Kluwer, 2018; 721-722.
Wu JP, Mao WL. Review of serum biomarkers and models derived from them in HBV-related liver
diseases. Dis Markers, 2020; 2020.
Yang Y, Wang L, Yan L, Zhang L, Zhou W, et al. Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross-sectional study. Exp Ther Med, 2020; 20(1): 243-50.
Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life-the
mechanism of inflammation triggering and long-term impacts. J Biomed Sci, 2015; 22(1): 1-7.
Wang J, Yan X, Yang Y, Chang H, Jia B, et al. A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B. Oncotarget, 2017; 8(35): 59257-67.
Huang R, Wang G, Tian C, Liu Y, Jia B, et al. Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI, FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China. Sci Rep
[Internet]. 2017; 7(1): 1-10. Available from: http://dx.doi.org/10.1038/s41598-017-09234-w (accessed at 5 June, 2020).
Lee J, Kim MY, Kang SH, Kim J, Uh Y, et al. The gamma-glutamyl transferase to platelet ratio and the
FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection. Br J Biomed Sci, 2018; 75(3): 128-32.
Hu YC, Liu H, Liu XY, Ma LN, Guan YH, et al. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol, 2017; 23(41):
-32.
Ren T, Wang H, Wu R, Niu J. Gamma-glutamyl transpeptidase-to-platelet ratio predicts significant
liver fibrosis of chronic hepatitis B patients in China. Gastroenterol Res Pract, 2017; 1-7.
Lian MJ, Zhang JQ, Chen SD, Zhang DD, Yang YY, Hong GL . D i agnos ti c a c c u r a c y of γ -gl u t a m y ltranspeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: A meta-analysis. Eur J
Gastroenterol Hepatol, 2019; 31(5): 599-606.
EASL. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017; 67: 370-98.
Chen Y, Li Y, Li N, Fan X, Li C, et al. A non-invasive score to predict liver fibrosis in HBeAg-positive hepatitis B patients with normal or minimally elevated alanine aminotransferase levels. Dis Markers, 2018; 2018.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
